AGED Diagnostics Liver Disease Assessment

Status unconfirmed · Early Phase 1

Conditions studied: NASH With Fibrosis, NAFLD, Healthy

In brief

Continue development of previously established methods to further validate candidate biomarkers that can discriminate steatosis from NASH and separately stage fibrosis from blood. The first assessment is to conduct test method verification to expand sample size to several hundred samples through whole genome sequencing methods. The second assessment is focused on biomarker validation by comparing targeted sequencing from patient plasma. Several sub- assessments will be conducted to support overall biomarker development efforts.

Key facts

Study ID
NCT06348563
Run by
Active Genomes Expressed Diagnostics, Corp
People needed
400
Starts
2024-05-15
Expected to finish
2025-09-15
Last updated by the study team
2024-04-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.